Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245333 | 0.86 | PIK3CD (0.41) | PTK2BLMNATNFPIK3CAPIK3CD | |
| SCHEMBL9910330 | 0.84 | PTK2B (0.45) | PTK2BRAF1BRAFTNFHCK | |
| SCHEMBL368862 | 0.81 | KDM4E (0.44) | LMNAMAPK14MEN1KMT2ANPC1 | |
| SCHEMBL29396841 | 0.81 | KDM4E (0.44) | LMNAMAPK14MEN1KMT2ANPC1 | |
| SCHEMBL14353634 | 0.81 | LMNA (0.63) | LMNAPIK3CAPIK3CDPIP5K1CPIK3CB | |
| SCHEMBL9909704 | 0.81 | PTK2B (0.41) | PTK2BRAF1BRAFTNFPIK3CD | |
| SCHEMBL13430425 | 0.80 | CDK8 (0.40) | LMNAMAPK12MAPK14MEN1KMT2A | |
| SCHEMBL20386628 | 0.80 | LMNA (0.43) | LMNAPIK3CAPIK3CDPIP5K1CPIK3CB | |
| SCHEMBL273437 | 0.80 | LMNA (0.65) | PTK2BLMNAMAPK12MAPK14MEN1 | |
| SCHEMBL15484918 | 0.79 | PIK3CD (0.42) | LMNAPIK3CAPIK3CDPIP5K1CPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732063-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9701670-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1480973-B1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7041669-B2 | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | PTK2B 231/4885LMNA 2716/4885RAF1 2/4885 |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | TSLP, CCL11, RORB | PTK2B 3147/4885LMNA 2963/4885RAF1 3197/4885 |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | IL1A, IL1B, XDH | PTK2B 4524/4885LMNA 2353/4885RAF1 1914/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PTK2B 482/4885LMNA 3490/4885RAF1 2/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | PTK2B 3147/4885LMNA 2963/4885RAF1 3197/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PTK2B 231/4885LMNA 2716/4885RAF1 2/4885 |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | PTK2B 198/4885LMNA 3242/4885RAF1 63/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | PTK2B 3147/4885LMNA 2963/4885RAF1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.